Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616774 | 0.82 | PDK2 (0.36) | NOS3NOS2NOS1PDK2PDK4 | |
| SCHEMBL23473993 | 0.78 | PDK2 (0.35) | NOS3NOS2NOS1PDK2PDK4 | |
| SCHEMBL21128112 | 0.78 | PDK2 (0.35) | NOS3NOS2NOS1PDK2PDK4 | |
| SCHEMBL175432 | 0.76 | RET (0.38) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL22582281 | 0.76 | IDO1 (0.46) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL12721815 | 0.76 | RET (0.38) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL12466822 | 0.76 | IDO1 (0.46) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL30508312 | 0.76 | DYRK1A (0.55) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL30440210 | 0.76 | RET (0.38) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL1585071 | 0.76 | DYRK1A (0.55) | RETPI4KAXDHLRRK2PI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129395-A1 | BTK INHIBITORS | GWYNANT THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-2729476-B1 | HETEROARYL SUBSTITUTED PYRAZOLOPYRIDINES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| US-20170158708-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-06-08 | — | — | US | disclosed |
| WO-2017046603-A1 | ANTIBACTERIAL COMPOUNDS AND NEW USES THEREOF | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046606-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017004342-A1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2015155549-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015112806-A2 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| WO-2014088519-A1 | COMPOUNDS INCLUDING MAP KINASE INTERACTING KINASES 1 AND 2 (MNK1 AND MNK2) MODULATORS AND ABL AND ABL (T315I) INHIBITORS, AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2014-06-12 | — | — | WO | disclosed |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | WANG GUOQIANG | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158708-A1 | ANTIBACTERIAL COMPOUNDS | ABCC1, SLC11A2, NQO2 | NOS3 1899/4885NOS2 1233/4885NOS1 1221/4885 |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | NOS3 84/4885NOS2 52/4885NOS1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.